Hans-Gunter Striegel

Title: The Innovations of Hans-Gunter Striegel

Introduction

Hans-Gunter Striegel is a notable inventor based in Blaubeuren, Germany. He has made significant contributions to the field of pharmaceuticals through his innovative work. His expertise and dedication have led to the development of unique compounds that have potential applications in medicine.

Latest Patents

Striegel holds a patent for a new crystalline modification of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-ylacetic acid, referred to as polymorph B. This invention is characterized by a peak in the solid state C-NMR spectrum, with adamantane as an external reference standard, showing a CH group at d=29.45 ppm in the range from 179.8 to 180.2 ppm. This polymorphic form can be processed directly into a pharmaceutical formulation, showcasing its practical utility in drug development.

Career Highlights

Striegel is associated with Merckle GmbH, a company known for its commitment to pharmaceutical innovation. His work at Merckle has allowed him to focus on developing new formulations that can enhance therapeutic efficacy. His patent reflects his ability to contribute to advancements in the pharmaceutical industry.

Collaborations

Throughout his career, Striegel has collaborated with esteemed colleagues such as Wolfgang Albrecht and Thomas Kammermeier. These partnerships have fostered an environment of innovation and have led to the successful development of new pharmaceutical products.

Conclusion

Hans-Gunter Striegel's contributions to the field of pharmaceuticals through his innovative patent demonstrate his commitment to advancing medical science. His work continues to impact the industry positively, paving the way for future developments.